Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Rheumatoid Arthritis Clinical Trial

Official title:

A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03890302
• Other study ID #: FB704ACLIS-01-RA
• Status: Completed
• Phase: Phase 1
• Start date: March 14, 2019
• Est. completion date: May 27, 2020

Study information

• Verified date: July 2020
• Source: Fountain Biopharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical in RA. This study investigates the drug FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2 sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part (Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in both parts will have a short stay in the clinic at the start of the study, then will return for outpatient visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: May 27, 2020
• Est. primary completion date: May 27, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subjects must provide written informed consent.

• No significant clinical, cardiac or physical abnormalities (Part 1 of study).

• Diagnosis of Rheumatoid Arthritis as defined by 2010 revised American College of Rheumatology (ACR) more than 3 months prior to start of study (Part 2 of study).

• If using oral corticosteroids (prednisone = 10mg or equivalent) and/or NSAIDS, subjects must be on stable dose(s) for at least 14 days prior to start of Part 2 of study and dose must be expected to remain stable through end of Part 2 of study.

• Subjects must be being treated with 1 or a combination of disease modifying antirheumatic drugs (DMARDs) methotrexate, leflunomide, sulfasalazine, and/or hydroxychloroquine (but not simultaneous use of leflunomide and methotrexate), at any dose for at least 28 days prior to start of Part 2 of study and on a stable dose(s) for at least 14 days prior to start of Part 2 of study.

• Subjects with documented RA that meet all inclusion criteria but are not taking DMARDs may be permitted in Part 2 of the study at the discretion of an investigator.

• Women of childbearing potential must agree to use one of the accepted contraceptive regimens from at least 30 days prior to first administration of the study medication, during the study, and for at least 60 days after last dose of the study medication.

• Women of non-childbearing potential should be surgically sterile or in a menopausal state (at least 1 year without menses).

• All males must agree to use highly effective contraception and to not donate sperm throughout the study and for 90 days following last dose of study medication.

• Subjects must have a body weight = 50 kg at screening and a body mass index (BMI) of 19.0 to 30.0 kg/m2, inclusive (Part 2 of study).

• Subjects must have not smoked or used any nicotine products for at least 3 months before screening (Part 1 of study).

Exclusion Criteria:

• Women who are pregnant or lactating.

• Subject has a past history of, or a history of risk factors for, heart arrhythmias or long QT syndrome.

• Subject has recurrent chronic serious infection, or has had a serious infection within 60 days of start of study.

• Subject has latent or active tuberculosis.

• Subject has received any live attenuated vaccine (e.g. varicella-zoster, oral polio, rabies, flu vaccine) within 3 months of start of study.

• Subject has received any biological drug or blood product within 3 months or 5 half-lives of start of study; or has received any other study drug within 30 days or 5 half-lives of start of study.

• Subject has previously been treated with any biologic, anti-interleukin-6 (anti-IL-6) or interleukin-6 receptor (IL-6) antagonist and/or has previous exposure to the study drug.

• Subjects with a documented history of an autoimmune disease other than rheumatoid arthritis or secondary Sjogren's syndrome.

Other protocol-defined inclusion/exclusion criteria could apply.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• FB704A
Administered by IV infusion
• Placebo
Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Locations

Country	Name	City	State
United States	Altasciences Clinical Kansas, Inc.	Overland Park	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Fountain Biopharma Inc.	Oneness Biotech Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events (AEs) (Part 1)		Up to Day 57
Primary	Incidence of Adverse Events (AEs) (Part 2)		Up to Day 99
Primary	Number of participants with clinical laboratory abnormalities (Part 1)		Up to Day 57
Primary	Number of participants with clinical laboratory abnormalities (Part 1)		Up to Day 99
Primary	Number of participants with physical examination abnormalities (Part 1)		Up to Day 57
Primary	Number of participants with physical examination abnormalities (Part 2)		Up to Day 99
Primary	Number of participants with dose limiting toxicities (DLT) (Part 1)		Up to Day 57
Primary	Number of participants with dose limiting toxicities (DLT) (Part 2)		Up to Day 99

External Links

•   FDA Safety Alerts and Recalls